UPDATE: Jefferies Reiterates Buy, Raises PT to $60 on UnitedHealth


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Jefferies maintains its Buy rating on UnitedHealth Group Inc. (NYSE: UNH) and raises its price target to $60 from $58 following an upbeat investor day showing long term growth opportunities. Jefferies says, “2013 is a "Break-Out" Year. Management called '13 the break-out year for Optum when OptumRx investments diminish and Medco comes on-line. We are more confident in UNH's accelerating EPS growth toward its LT target of 13-16%. UNH is positioned to address a growing MA population, Medicaid RFPs, dual eligibles ($300bn), and the exchanges ($60bn in 2014).”In a statement provided to Benzinga for clarification, the reference of Medco coming "on-line" is defined as Medco's pharmacy benefit services being brought in-house. As quoted from

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

this article from the Associated Press, "UnitedHealth will spend $115 million on its OptumRX business next year, as it prepares to handle pharmacy benefits it used to give to Medco Health Solutions, Inc."UNH closed at $45.88 per share on Tuesday.
Posted In: Analyst ColorPrice TargetPre-Market OutlookAnalyst RatingsJefferies & CompanyOptum